Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Ormutivimab

Catalog #:   DVV03905 Specific References (7) DATASHEET
Host species: Human
Isotype: IgG1, lambda2
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DVV03905

Expression system

Mammalian Cells

Species reactivity

Rabies virus (RABV)

Host species

Human

Isotype

IgG1, lambda2

Clonality

Monoclonal

Target

G, Glycoprotein

Concentration

1.99 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O92284, P08667

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

NM57, rhRIG CAS: 2449086-91-1

Clone ID

Ormutivimab

Data Image
References

The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study., PMID:39710015

Pharmacokinetic study and preliminary evaluation of safety and efficacy of the recombinant human monoclonal antibodies against rabies virus (rhRIG) in Chinese healthy population: A randomized, single-blinded, placebo-controlled phase Ia clinical trial., PMID:37778451

Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus., PMID:37427985

Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial., PMID:37211270

Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase Ⅱb randomized, double-blind, parallel-controlled study., PMID:36123259

Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects., PMID:36016106

Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models., PMID:35091118

Datasheet

Document Download

Research Grade Ormutivimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Ormutivimab [DVV03905]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only